



FOR IMMEDIATE RELEASE

CAMBRIA BIOSCIENCES ANNOUNCES COLLABORATION WITH PFIZER ANIMAL HEALTH IN ANTIPARASITIC DRUG DISCOVERY

WOBURN, MA - June 7th, 2007 - Cambria Biosciences LLC, a Boston-area CNS drug discovery company, today announced a research collaboration agreement with Pfizer Animal Health to guide the discovery and development of new classes of safe and effective antiparasitic drug products.

Cambria Biosciences will use its chemical genetics platform to elucidate the molecular targets — and important functional sites within those targets — that have responded to Pfizer's candidate parasitocidal compounds. The compounds have potentially novel modes of action that could overcome the resistance that parasites have developed to many current medicines.

Existing antiparasitic drugs act through a limited number of biochemical modes of action (MOA), all of which are threatened by increasing levels of drug resistance observed in the field. Thus, discovering and developing new antiparasitic drugs with novel modes of action is an industry-wide priority.

In helping Pfizer Animal Health identify the molecular targets of its novel candidate parasiticide products, Cambria's genetic technologies offer numerous benefits. These include: strategies for identifying additional compounds with similar activity; accelerated market adoption through distinct product positioning; detailed safety profiles and benefit/risk ratios for regulatory agencies; and the potential for optimizing second-generation products for the novel molecular targets.

In addition, Cambria's chemical genetic platform can create predictive models for the emergence and mode of compound resistance to aid in the field management and veterinary practice recommendations for an eventual product.

Under the terms of the present agreement, Pfizer Animal Health will provide milestone payments to Cambria for this program. Financial terms were not disclosed.

Dr. Andrew Weatherly, Director of Veterinary Medicines R&D at Pfizer, stated, "We were encouraged by the speed and quality of Cambria's model systems approach. Innovation is critical to us, in order that we can accelerate the discovery and development of safe, effective products to protect livestock and companion animals."

"Our work with the Pfizer compounds will be the latest in a series of chemical genetic studies by Cambria that is uncovering unprecedented pharmaceutical targets," said Dr. Ann Sluder, Cambria's Director of Biology. "We look forward to helping Pfizer advance, protect and position its product pipeline for launch."

Dr. Leo Liu, President and CEO of Cambria Biosciences, noted, "We are pleased that the experience and skills in chemical and genetic discovery that we have used to build our internal product pipeline for human neurological indications can also be leveraged to help companies such as Pfizer Animal Health improve the health and well-being of animals around the world."

About Cambria Biosciences

Cambria Biosciences is an innovative biotechnology company building a product pipeline for neurodegenerative conditions such as Lou Gehrig's disease and epilepsy. Cambria also employs its chemical genetics platform to aid animal health and agricultural companies advance their pipelines, differentiate their products and reduce the risks of field resistance through a precise understanding of their candidate products' mode of action. Further information is available at www.cambriabio.com.

About Pfizer Animal Health

With 2006 sales of \$2.3 billion, Pfizer Animal Health is a global leader in discovering, developing and marketing medicines and vaccines for companion animals and livestock, including beef and dairy cattle and swine. Further information is available at www.pfizerah.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the respective company's control which may cause actual results, performance or achievements of that company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by regulatory authorities, and other activities.

For further information, contact

Cambria Biosciences
Carol Zepp
Corporate Communications
czepp@cambriabio.com
978-468-8080

MacDougall Biomedical Communications
Kari Watson
kwatson@macbiocom.com
508-647-0209